The Biggest Potato Recalls In US History
The potato is a modest yet mighty food that has captured hearts and stomachs the world over. If a sack of potatoes isn't one of your personal pantry staples, there's a chance that another potato-based item is, because quite frankly, potatoes are the main ingredient in a lot of popular foods. That's why recalls that affect potato products sold in the U.S can affect food brands on a humongous scale.
Potato chips rank among the most popular snacks in the U.S., and hash browns are considered as a staple side for egg dishes. With these two examples alone, it's clear why several food manufacturers make millions of dollars just from selling potato-based foods. If one of these companies has to issue a recall of one or more of its products, immense amounts of retail-bound goods become unsalable. Recalls create huge financial losses in the business world, but they are a necessary precaution to keep the public safe.
Food recalls happen when a commercially sold product does not meet the federal regulations upheld by the Food and Drug Administration (FDA) and/or the United States Department of Agriculture (USDA). Contaminations from either foodborne pathogens or foreign materials, undeclared ingredients, and quality issues stemming from mold or spoilage are common recall reasons for many products — including foods made with potatoes. These are some of the biggest recalls to ever take place in the U.S. that involved potato-based products.
Read more: Campbell's Chunky Soup Flavors, Ranked Worst To Best
Among the many producers of frozen breakfast foods, herbivore favorite Veggies Made Great was on a roll selling frittatas and other morning-meal goodies in U.S. grocery stores — until a massive recall in May 2024 threw a wrench in the operation. The recall dealt specifically with the brand's Broccoli Cheddar Breakfast Potato Bakes, which were being called back over a suspected contamination from listeria monocytogenes (L. monocytogenes). This pathogen is particularly dangerous to perishable foods because it can survive in cold — even freezing — temperatures for prolonged periods of time. After the recall announcement, Veggies Made Great began pulling boxes off of store shelves.
The quantity of recalled Broccoli Cheddar Breakfast Potato Bakes was significant — 10,544 boxes in all. Veggies Made Great sells its products through major retailers like Walmart, Target, and Costco, as well as many other popular grocery chains. The boxes that were possibly contaminated by L. monocytogenes were only sold in Arizona, California, Colorado, New Mexico, Nevada, and Utah.
This voluntary recall was issued by Veggies Made Great's parent company, New Classic Cooking LLC in Avenel, New Jersey. New Classic Cooking previously sold Veggies Made Great frozen products as a sub-brand of its Garden Lites label. The company did not divulge how L. monocytogenes may have adulterated the Broccoli Cheddar Breakfast Potato Bakes, or if any illnesses were linked to the recall.
Since its founding in 1950 in Weston, Oregon, Lamb Weston has become one of the world's largest manufacturers of frozen potato products, with distribution to over 100 nations. The magnitude of Lamb Weston's output was emphasized in August 2022 when a recall of more than 1 million pounds of shredded hash browns was issued. The hash browns were at risk of contamination from L. monocytogenes — the bacteria that causes the foodborne illness listeriosis.
The recalled product was sold under the Alexia line as Organic Seasoned Hashed Browns Yukon Select Potatoes, as well as Great Value Shredded Hash Browns, Sprouts Organic Hash Browns Shredded Potatoes, and True Goodness by Meijer Organic Hash Brown Shredded Potatoes. Overall across the retail market, 1,087,200 pounds of hash browns were recalled. Alexia was hit the hardest, with 90,600 cases of hash browns recalled. Great Value, Walmart's in-house label, recalled 7,377 cases. Sprouts recalled 13,313 cases, while True Goodness by Meijer recalled 1,361 cases. The frozen potatoes were sold nationwide and in Guam, and in other countries throughout the Americas, East Asia, and the Middle East.
There were also non-retail hash browns to consider. Lamb Weston sold potentially dangerous shredded hash browns to food service institutions under the Lamb's Supreme Shredded IQF Hash Browns line. In a letter to customers, Lamb Weston disclosed that L. monocytogenes was found during product sampling, and may have affected shipments of hash browns dating back to February 2021.
Mega potato purveyor Lamb Weston was also in trouble in April 2019, only this time its Supreme Tater Puffs were the problem. Since Lamb Weston cranks out an immense amount of frozen potato products, gargantuan recalls don't derail its operations. With this recall, Lamb Weston recalled over 680,000 pounds of frozen tots due to contamination by a foreign object ... and hardly anyone batted an eye.
In addition to selling its frozen spuds in grocery stores worldwide, Lamb Weston also sells products to institutions with cafeterias, such as hospitals and schools. The five-pound paper bags of Lamb's Supreme Tater Puffs that it sold on the non-retail market were the ones that needed recalling. The foreign object that afflicted these cafeteria-bound tots was plastic. The recall resulted in 22,789 cases of Lamb's Supreme Tater Puffs — distributed in 19 states — as being deemed unfit for consumption.
Foreign contaminants posed a huge obstacle to Lamb Weston's production in 2019. A month prior to this recall, 76,740 pounds of Lamb's Supreme Starz Hash Brown Patties were recalled for that very reason. And in November 2019, 72,576 pounds of Lamb Weston's Grown In Idaho Crispy Hash Brown Dices were recalled due to containing pieces of rubber.
Ore Ida is a household name in prepackaged potato products, but the frozen Spud Bites that were recalled in September 2019 weren't sold in stores. After it was determined that some five-pound bags of Spud Bites shipped in unlabeled food-service bags may contain pieces of a hard foreign material, the product was declared unfit to serve. The voluntary recall was issued by Ore Ida's parent company, McCain Foods. In total, 84,900 pounds of Spud Bites were implicated in the recall.
McCain Foods manufactures potato-based products under its Ore Ida label, and while the company initiated this recall, it never publicized what the foreign contaminant was made of. However, this problem is not uncommon — during the first six months of 2019 alone, the amount of food recalled in the U.S. due to foreign-material contaminants totaled over 13 million pounds. Some of the most common foreign materials that sneak into food and cause recalls are plastic, metal, and rubber. Experts point to an increase in automated machinery on processing plant assembly lines as a primary culprit in foreign contaminant recalls.
McCain launched the Ore Ida Spud Bites recall in a timely manner, and the FDA terminated the recall on April 30, 2020. The afflicted Spud Bites were distributed in Indiana, Kansas, Mississippi, Ohio, Pennsylvania, and Virginia.
If thousands of cases of frozen hash browns were recalled and you didn't hear about it in the news, this was likely because the recall came from Lamb Weston. For years, slip-ups in quality control have forced Lamb Weston — an international producer of frozen potato goods — to initiate massive recalls of its products, yet the company has largely managed to keep these recalls out of the press. The recall for its hash brown patties in September 2018 was a big one — 8,059 cases, to be exact. The hash browns were recalled because they possibly contained fragments of hard, clear plastic.
Lamb Weston sold the recalled hash brown patties under the product names Brookshire's Golden Hash Brown Patties, Hill Country Fare Breakfast Hash Browns Potato Patties, Market Pantry Hash Brown Patties, and Stater Bros. Hash Brown Patties Shredded Potatoes. The frozen hash browns were packed in cardboard trays and wrapped with plastic film. They were distributed to California, Florida, Iowa, Massachusetts, Maryland, Ohio, Pennsylvania, and Texas.
The FDA gave the recall a Class II designation due to the plasticky hash browns' capacity to cause temporary health damage to consumers. It appears that nobody was injured in relation to this recall of hash brown patties, which may be one of the reasons Lamb Weston has been able to keep its recall history on the down-low.
Many processed foods rely on a chain of suppliers to provide the ingredients that make iconic products what they are. This requires food companies to place a certain amount of trust in its chosen suppliers — and sometimes things don't go according to plan. When prominent U.S.-based milk powder supplier Valley Milk started churning out mass amounts of salmonella-contaminated milk powder in 2016, the ramifications rocked the potato chip industry. The food recalls that followed were enormous.
Multiple chip brands had tapped Valley Milk for milk powder to flavor potato chips. When Valley Milk announced a recall for its nonfat dry milk powder and sweet cream buttermilk in December 2016, more than a dozen chip varieties were recalled in connection to the compromised product. Old Dutch Foods — which sells chips under its own name brand, as well as Lund's & Byerly's, Urge, and Roundy's — recalled 2,513,706 units due to the Valley Milk recall. At the same time, Shearer's Foods recalled classic potato chips sold under several brand names, including Deep River, Larry the Cable Guy, Essential Everyday, and Delish.
This all originated from an investigation by the FDA into Valley Milk's production plant in Strasburg, Virginia. The authorities found this plant to be unsanitary, and they used whole genome sequencing (WGS) to trace salmonella-tainted products containing Valley Milk-supplied milk powder to the facility. Once confirmation was received, the FDA seized over 4 million pounds of Valley Milk products — the value of which was worth almost $4 million.
Potato chip brands that seasoned their chips with hydrolyzed vegetable protein (HVP) produced by Basic Food Flavors, Inc. were in a tough spot in 2010. The Las Vegas-based company recalled its HVP in February 2010, after a company that purchased and analyzed the product notified the FDA that the HVP tested positive for salmonella. News of the recall prompted numerous brands that sold potato chips containing Basic Food Flavors' HVP to launch secondary recalls.
Companies recalled chips in massive quantities. North Carolina-based chip brand Lance recalled 28,087 cases of its Tom's Barbecue Potato Chips from 34 states. Herr's Potato Chips — based in Pennsylvania — pulled two batches of its Cracked Pepper and Sea Salt Flavored Kettle Style Potato Chips from shelves as a precaution. Procter & Gamble recalled two limited-edition Pringles flavors — Restaurant Cravers Cheeseburger and Family Faves Taco Night — because they contained HVP supplied by Basic Food Flavors.
Potato chips were among over 100 product recalls associated with the Basic Food Flavors salmonella crisis. The FDA investigated the Basic Food Flavors facility and found the presence of salmonella. Following the investigation, the FDA alleged that the company was made aware of the salmonella bacteria in its processing facility and continued selling HVP anyway. Basic Food Flavors has vehemently denied this. As for how much HVP was recalled by the FDA? The company's sales and marketing manager told FoodNavigator-USA that "only 10,000 pounds of 10 million" was affected.
Few canned soup brands command household-name status to the level that Campbell's does — but a recall initiated on October 4, 2007 threatened to put a dent in the company's reputable legacy. The recall involved just one soup flavor: Campbell's Chunky Baked Potato with Cheddar & Bacon Bits. Campbell's had to recall 72,300 cans of this potato soup because there was one chunky ingredient inside that didn't belong: hard plastic pieces.
The recall created a huge amount of unsellable inventory for the brand, which had been producing a selection of Campbell's Chunky soup flavors since 1970. The recalled 18.8-ounce cans had already been shipped to 24 states before the recall was announced. In fact, the plastic pieces in the potato soup were brought to the attention of Campbell's following customer complaints.
Potato-based product recalls can be massive, yet many companies manage to get through the recall period without any related reports of consumer illness or injury. Campbell's wasn't so lucky. Prior to the recall announcement, the company received three reports of injury in or around the mouth because consumers ended up chomping on plastic pieces hidden within the thick soup. Campbell's eventually cleared up its plastic problem, and Chunky Baked Potato with Cheddar & Bacon Bits remain part of the lineup of Campbell's Chunky soup flavors.
When Minnesota-based company Northern Star recalled tens of thousands of pounds of frozen hash browns on December 22, 2004, food recalls were not the perpetual occurrence that they are today. Northern Star, which was established in 1951 and now operates as a subsidiary of Michael Foods, initiated a recall for Simply Potatoes Plain Shredded Hash Browns — one of the brand's signature products. The recall was needed after fragments of glass were found inside the hash brown bags.
It is the goal of every food manufacturer to catch any deviances in product quality before that product hits the retail market, yet all too often it doesn't work out that way. Northern Star had no choice but to address its subpar production practices after it received complaints that four bags of Simply Potatoes Plain Shredded Hash Browns sold in South Dakota were adulterated by bits of glass. The amount of recalled hash browns totaled 49,932 pounds. Northern Star's recall affected two product lots of these hash browns sold in 35 states. Despite the glass-contaminated product being within reach of consumers, no injuries were reported in relation to the recall.
Potato bread's origins date back to 18th-century Europe, but it is best known by today's consumers as the plastic-wrapped sandwich loaf with a yellowish hue. Dutch Country potato bread is sold by multiple food producers, yet it was the version from George Weston Bakeries that was behind a big-time recall in January 2004. The recall was issued for undeclared allergens.
The year 2004 saw landmark changes in how the U.S. approaches federally regulated food labels. After years of observing consistent omissions of major food allergens on product packaging, the FDA helped launch the Food Allergen Labeling and Consumer Protection Act of 2004, requiring all companies selling food products in the domestic marketplace to print allergen warnings on packages of food containing milk, soy, wheat, eggs, fish, shellfish, peanuts, or tree nuts. When packages of Dutch Country Soft Potato Bread produced by George Weston Bakeries were found to contain undeclared soy flour, whey protein, and milk, a huge recall was in order.
George Weston Bakeries removed 250,533 pounds of Dutch Country Soft Potato Bread from distribution on account of the product mislabeling. Recalling over a quarter of a million pounds of potato bread is a hard-knocks lesson for any food brand, but George Weston Bakeries appeared to take it in stride — for a while. In December 2021, George Weston sold its stake in the fresh and frozen bakery industry to FGF Brands Inc. for $1.1 billion.
The complicated relationship between the FDA and artificial food dyes has been going on for decades — in fact, the history of Red Dye No. 3 is intertwined with the FDA. Food manufacturers are perpetually drawn to these man-made color compounds as a way to give processed foods a visual glow-up for cheap and easy. This has been allowed in the U.S. as long as the manufacturer discloses the use of artificial coloring in its ingredients list. When the major sweet potato brand Bright Harvest forgot to be explicit in the fine print of its Candied Sweet Potatoes in 2003, it triggered one of the largest potato recalls in our nation's history.
There are lots of great sweet potato recipes out there, but sometimes convenience takes precedence and leads shoppers to the canned versions of popular sweet potato sides. When that happened, Bright Harvest was there to answer the call ... most of the time. On December 11, 2003, Bright Harvest's Candied Sweet Potatoes were recalled because they contained undeclared Yellow 6. This chemical food dye remains prevalent in processed foods to enhance the bright tones of myriad edible products. It's a legal additive in the U.S. — as long as its inclusion is listed on product packaging.
Bright Harvest's oversight caused 174,531 pounds of its Candied Sweet Potatoes to be removed from retail distribution. For some 40 years, the company, based out of Clarksville, Arkansas, was a leading manufacturer of sweet potatoes in the U.S. Today, the company no longer appears to be in business.
When industrialized processed potato products were in their infancy, J.R. Simplot was a trailblazer. His company supplied millions of pounds of dehydrated potatoes and onions to the U.S. military during World War II. Fast-forward to February 2003, and the J.R. Simplot Company was on the hook for a huge potato recall after hard plastic pieces were found in its frozen hash browns. The hash browns were sold under the Simplot label, as well as Nestlé and Lynden Farms.
Since it was 2003, J.R. Simplot's production error wasn't plastered across every digital news outlet then servicing the World Wide Web. Instead, the venerable company discreetly recalled 67,577 pounds of plastic-plagued hash browns. The recall was given a Class II designation by the FDA due to the choking hazard and potential for mouth injury that the plastic pieces presented. However, the recall apparently didn't cause long-term damage to company operations. The J.R. Simplot Company continues to thrive, primarily selling its frozen potato products to a wide range of food service institutions.
Read the original article on Mashed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
6 hours ago
- Associated Press
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS). This marks the second registrational Phase III study of lisaftoclax to receive clearance from both the FDA and EMA. The GLORA-4 study is simultaneously enrolling patients at participating centers in multiple countries, to accelerate the drug's path to potential market authorization. To date, lisaftoclax is the only Bcl-2 inhibitor being advanced in a registrational Phase III trial in higher-risk MDS globally. This study, if positive, may potentially end the longstanding treatment gap in higher-risk MDS, marking yet another major milestone in the global clinical development of lisaftoclax. Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, 'Globally, we still lack targeted therapies for first-line treatment of patients with higher-risk MDS, which represents a huge unmet clinical need. Currently, hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain the primary treatment options for higher-risk MDS. In earlier studies, lisaftoclax has demonstrated promising clinical benefit and tolerability. The clearances of the GLORA-4 study by the U.S. FDA and EMA, coinciding with the approval by the China CDE, pave the way for lisaftoclax to potentially become the first Bcl-2 inhibitor approved globally for first-line treatment of higher-risk MDS and the first targeted therapy approved for this indication since the introduction of HMA, which fundamentally reshapes the treatment landscape.' The GLORA-4 trial is being conducted simultaneously in China, the U.S., and Europe. This will significantly accelerate the clinical development of lisaftoclax in MDS and accelerate the drug's path to potential market authorization. Moving forward, we will remain steadfastly committed to our mission of addressing unmet clinical needs in China and around the world, actively advancing our clinical programs for the benefit of more patients.' GLORA-4 is a multi-region, multi-center, randomized, double-blind Phase III trial designed to evaluate the efficacy and safety of lisaftoclax in combination with AZA compared to placebo plus AZA in newly diagnosed adult patients with higher-risk MDS. The study was originally approved by the China CDE in 2024. Currently, the study is enrolling patients globally, with the first patients already enrolled in China and Europe. Guillermo Garcia-Manero, MD, Chair of the Department of Leukemia, The University of Texas MD Anderson Cancer Center (MDACC), and Prof. Xiaojun Huang, MD, an academician of the Chinese Academy of Engineering, director of the Institute of Hematology at Peking University, and director of the Department of Hematology at Peking University People's Hospital, are global co-leading principal investigators of the study. MDS is a myeloid clonal disease originating from hematopoietic stem cells with strongly age-correlated characteristics. Global epidemiological data of MDS show an exponential increase in incidence with age (22/100,000 in the population aged over 65 years), with a median age of diagnosis of 70 years1. More than 75% of patients with MDS present a complex disease profile that includes at least two comorbidities2. The primary risk of MDS is clonal evolution leading to progression to acute myeloid leukemia (AML), with 40-60% of higher-risk patients (high/very high risk, as classified by IPSS-R) progressing to AML within five years3. These patients have a dismal prognosis and a median survival of less than six months4. As the standard first-line therapy for higher-risk MDS, HMAs offer inadequate responses to treatment, with an overall response rate (ORR) of just 30-40%5, a complete response (CR) rate of 10-17%, and a median duration of response of 9-12 months6, 8. While allo-HSCT can offer a potential cure, it is limited by the median age of patients, complex disease profiles, common depletion of the hematopoietic stem cell reserve, and a transplantation-related mortality (TRM) rate of 25-35%. As a result, only 5-10% of eligible patients can receive transplantation7. The five-year survival rate of patients who are classified by the IPSS-R as high-risk remains at 16-24%8, highlighting an urgent unmet medical need for innovative therapies that can change the treatment paradigm. Lisaftoclax is a proprietary, novel, orally administered Bcl-2 selective inhibitor being developed by Ascentage Pharma to treat patients with malignancies by selectively blocking the anti-apoptotic protein Bcl-2 and restoring the normal apoptosis process in cancer cells. Lisaftoclax is already approved in China for adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy, including Bruton's tyrosine kinase (BTK) inhibitors. Previously, the Company released the clinical data of lisaftoclax in combination with AZA in treatment-naïve (TN) MDS during the 2024 American Society of Hematology (ASH) Annual Meeting and the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showed an ORR of 75%, much higher than HMAs alone, which demonstrated the clinical benefit of the combination regimen. The combination also showed a favorable safety profile, with a low incidence of severe hematologic toxicities and neutropenia-related infections. In addition, the proportion of patients requiring dose adjustments was low and there were no treatment-related mortalities within 60 days9, 10. Professor Huang commented, 'Despite the significant advancement in the treatment of hematologic malignancies, higher-risk MDS remains a major clinical challenge because of a range of factors. First, the current standard of care treatment with HMAs only offers limited efficacy, with just about one-third of patients achieving a response to treatment. Second, no breakthrough therapies have emerged globally in the two decades since the introduction of HMAs. As a result, there is an unmet clinical need for targeted therapies for higher-risk MDS. The compelling response rate and manageable safety profile observed in earlier studies of lisaftoclax are very encouraging. We hope this global Phase III study has the potential to provide new insights that could benefit how we treat and manage higher-risk MDS.' Dr. Garcia-Manero commented, 'Higher-risk MDS is more prevalent in older populations and thus presents unique clinical challenges. These patients often have multiple comorbidities and depleted hematopoietic reserves, making them less tolerant of treatment with particularly high requirement for safety. Preliminary clinical data of lisaftoclax demonstrated notable clinical benefit, with low rates of treatment-related dose adjustments and mortalities while maintaining significant response rates. We hope these characteristics of lisaftoclax will make it a potentially superior treatment option for patients.' References: About Ascentage Pharma Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST. The second lead asset, lisaftoclax, is the first China-approved third-generation Bcl-2 inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy, including Bruton's tyrosine kinase (BTK) inhibitors. The Company is currently conducting 4 global registrational Phase III trials: the GLORA study of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL who were previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed elderly and unfit patients with AML; and the GLORA-4 study in patients with newly diagnosed higher-risk MDS. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contact Information Investor Relations: Hogan Wan, Head of IR and Strategy Ascentage Pharma [email protected] +86 512 85557777 Stephanie Carrington ICR Healthcare [email protected] +1 (646) 277-1282 Media Relations: Jon Yu ICR Healthcare [email protected] +1 (646) 677-1855
Yahoo
8 hours ago
- Yahoo
MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline
We recently published . MannKind Corporation (NASDAQ:MNKD) is one of the best healthcare stocks. MannKind Corporation (NASDAQ:MNKD)'s most recent milestone is its push to expand the use of its rapid-acting inhaled insulin, Afrezza, to pediatric patients. In August 2025, the company submitted a supplemental Biologics License Application to the FDA for use in children ages 4–17, supported by positive Phase 3 INHALE-1 trial results presented at major diabetes conferences. A regulatory decision is expected in Q4 2025. Clinical data from both pediatric (INHALE-1) and adult (INHALE-3) studies have reinforced Afrezza's efficacy and safety across age groups. These advances have also helped the business gain attention among investors looking at the best healthcare stocks. Beyond Afrezza, MannKind Corporation (NASDAQ:MNKD) is advancing its pipeline in respiratory and rare diseases. MNKD-101, an inhaled clofazimine for nontuberculous mycobacterial lung disease, is progressing ahead of schedule in its global Phase 3 ICoN-1 trial. MNKD-201, a therapy for idiopathic pulmonary fibrosis, is set to enter Phase 2 testing by the end of 2025. Copyright: nicoletaionescu / 123RF Stock Photo To support these initiatives, the business secured up to $500 million in non-dilutive financing from Blackstone in August 2025. This funding will accelerate the potential launch of pediatric Afrezza, expand its commercial capabilities, and advance its clinical programs. Together, these developments position MannKind Corporation (NASDAQ:MNKD) for growth in both diabetes care and specialty lung disease markets. While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
8 hours ago
- Yahoo
ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates
We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best healthcare stocks. ImmunityBio, Inc. (NASDAQ:IBRX) is among the best healthcare stocks. It is a clinical-stage biotech company developing advanced immunotherapies and vaccines targeting cancers and infectious diseases by activating immune cells such as natural killer and T cells. A key recent milestone is the FDA-approved immunotherapy drug ANKTIVA for bladder cancer, specifically for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS). ANKTIVA, designated a Breakthrough Therapy, is expanding its clinical use, notably with the Michael E. DeBakey VA Medical Center in Houston becoming one of the first VA hospitals to administer the treatment to veterans, a population at higher bladder cancer risk. In Q2 2025, ImmunityBio, Inc. (NASDAQ:IBRX) reported a 60% revenue growth quarter-over-quarter, reaching $26.4 million and a year-to-date total of approximately $43 million. This growth is driven by increased commercial momentum post-approval and supported by an $80 million capital raise in July 2025 to fuel ongoing development and expansion. ImmunityBio, Inc. (NASDAQ:IBRX) is transitioning from a clinical-stage biotech to a commercial-stage company with ANKTIVA's expanding adoption, including recent UK regulatory approval for ANKTIVA plus BCG. The drug addresses an underserved cancer indication with the potential to reduce invasive treatments like cystectomy, backed by clinical data showing durable bladder preservation up to 36 months in responders. While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data